KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Revenue: 2012-2024

Historic Revenue for Travere Therapeutics (TVTX) over the last 13 years, with Dec 2024 value amounting to $233.2 million.

  • Travere Therapeutics' Revenue rose 162.11% to $164.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $435.8 million, marking a year-over-year increase of 114.22%. This contributed to the annual value of $233.2 million for FY2024, which is 60.55% up from last year.
  • As of FY2024, Travere Therapeutics' Revenue stood at $233.2 million, which was up 60.55% from $145.2 million recorded in FY2023.
  • In the past 5 years, Travere Therapeutics' Revenue ranged from a high of $233.2 million in FY2024 and a low of $12.0 million during FY2021.
  • In the last 3 years, Travere Therapeutics' Revenue had a median value of $145.2 million in 2023 and averaged $162.6 million.
  • Its Revenue has fluctuated over the past 5 years, first plummeted by 93.95% in 2021, then soared by 812.17% in 2022.
  • Over the past 5 years, Travere Therapeutics' Revenue (Yearly) stood at $198.3 million in 2020, then tumbled by 93.95% to $12.0 million in 2021, then spiked by 812.17% to $109.5 million in 2022, then soared by 32.69% to $145.2 million in 2023, then soared by 60.55% to $233.2 million in 2024.